However, the incidence of MAS in the trials was similar to the incidence of MAS in sJIA patients reported from a tertiary care pediatric rheumatology center in the US, which suggested that IL-1 inhibition with CNK does not have a major effect on the risk of developing MAS. This evidence concerns the gene IL1B and macrophage activation syndrome.